Short communication

Cloning and expression of VP2 gene of Infectious bursal disease virus in eukaryotic cells

Roozbeh Hushiarian[1], Mohammad Roayaei[1], Hamid Galehdari[1*], Masoud Reza Seyfiabad Shapouri[2]

[1]Department of Biology, Faculty of Sciences, Shahid Chamran University of Ahvaz, P.O. Box 65355-141, Ahvaz, I.R. Iran [2]Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, P.O. Box 65355-145, Ahvaz, I.R. Iran

Abstract
Infectious bursal disease (IBD) is an economically important viral disease of chickens with worldwide distribution which suppresses the immune system of young chickens. VP2 is the major host-protective protein of infectious bursal disease virus (IBDV). The encoding region of VP2 protein was PCR amplified from a plasmid containing a cDNA fragment of large genomic segment of IBDV, strain D78. This region of 1356 bp was inserted into a eukaryotic expression plasmid, pCDNA4, under the control of human cytomegalovirus (hCMV) immediate early enhancer and promoter. Plasmid DNA was transfected into COS-7 cell line and transient expression of VP2 from the constructed plasmid was characterized by dot blotting with a polyclonal antibody to IBDV.
Keywords: Infectious bursal disease; IBDV; VP2; eukaryotic expression; pCDNA4; COS-7 cell line.

Infectious bursal disease (IBD), also popularly known as Gumboro disease, is an acute, contagious viral disease of chicken (Kibenge *et al*., 1988), caused by a double-stranded RNA virus of the *Birnaviridae* family (Murphy *et al*., 1995). The genome of IBD virus (IBDV) consists of two segments, designated A and B. Segment A contains two overlapping open reading frames (ORF). The larger ORF of the segment encodes a polyprotein consisting of VP2, VP4 and VP3. VP2 is a major capsid protein eliciting neutralizing antibodies. Segment B codes for a 97 kDa protein, designated as VP1, which represents the viral RNA-dependent RNA polymerase (Kibenge *et al*., 1991).

IBDV targets the lymphoid tissue of chickens, mainly the bursa of fabricious, causing severe bursal damage, and consequently suppresses the immune system. Thus, IBD is of major economic importance to the poultry industry. Following the appearance of so virulent strains of IBDV, it was evident that conventional IBDV vaccines could not protect chickens and therefore, less attenuated intermediate and hot vaccines were developed. These vaccines may have some pathogenic characters and induce moderate bursal atrophy. In addition, they might be able to revert to a virulent state (Tsukamoto *et al*., 1995; Lukert and Saif, 1997).

In order to circumvent the potential disadvantages of live vaccines against IBDV, many studies have been performed to develop more potent vaccines, based on recombinant DNA technology (Jagadish *et al*. 1988, Goudarzi *et al*., 2006; Shaw and Davison, 2000).

In the 1990s, an entirely new type of vaccine (DNA vaccines) was first described (Wolff *et al*., 1990;Robinson *et al*., 1993; Ulmer *et al*., 1993). These new vaccines used naked plasmid DNA to express foreign proteins in the host. DNA vaccines are specially modified bacterial plasmids that usually have an *Escherichia coli* origin of replication, an antibiotic resistant gene, eukaryotic promoter that drives the expression of the target gene, a target gene and a polyadenylation signal sequence. The target gene usually codes for an antigenic protein from a pathogenic infectious organism. Since these initial reports on this

*Correspondence to: **Hamid Galehdari,** Ph.D.
Telefax: 06113331045
E-mail: galehdari@scu.ac.ir

novel vaccine technology, DNA vaccines have been successfully used to immunize a number of different animal species against a multitude of infectious agents (Corr *et al*., 1996; Sakaguchi *et al*., 1996; Scholz *et al*., 1993; Fynan *et al*., 1993) DNA vaccines have also been successfully used in poultry to immunize against several pathogens (Robinson *et al*., 1993; Sakaguchi *et al*., 1996; Fynan *et al*., 1993).

E. coli strain TOP10F' was cultured routinely at 37 ºC in broth or on agar plates of LB medium supplemented, with 50 µg/ml ampicillin, if required . A plasmid DNA (pTZ57RVP2) containing the VP2 cDNA of IBDV, strain D78 (Goudarzi *et al*., 2006)) was used for PCR amplification of VP2 cDNA. A eukaryotic expression vector, pCDNA4, was applied for cloning and expression of VP2 gene in eukaryotic cells. COS-7, a fibroblast-like cell line, transformed by an origin-defective mutant of SV40 which codes for wild-type T antigen of SV40 was used in transfection studies. This cell line was cultured in Dolbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS, maintained at 37°C and 5% CO_2.

The plasmid DNA pTZ57RVP2 was extracted from bacterial strain TOP10F' by Roche Plasmid Mini preparation Kit. The VP2 coding region of this plasmid was amplified by forward (5′-GCCGGAATTCATGACAAACCTGCAAGAT-3′) and reverse (5′-GCCGTCTAGAAACCTTATGGCCCGGAT-3′) oligonucleotide primers designed for cloning of the gene in pCDNA4 plasmid, downstream of a 6× Histidines tag sequence. The first ATG and the C-terminal stop codons of VP2 are underlined. For directional cloning, *Eco*RI and *Xba*I restriction sites were added at the 5′ ends of the forward and reverse primers, respectively. The cycling parameters were an initial denaturation at 100ºC for 5 min followed by 30 cycles of denaturation at 95ºC for 1 min, annealing at 58ºC for 1 min and extension at 72ºC for 1 min. The final cycle was followed by a long extension at 72ºC for 10 min. The amplified VP2 fragment (1365bp) and pCDNA4 vector were digested with *Eco*RI and *Xba*I and ligated after purification from a 1% agarose gel. The resulting DNA construct was designated as pCDNA4VP2 and used for transformation of competent TOP10F' *E. coli* cells. In order to confirm that no errors were introduced as a result of PCR amplification, complete sequence of VP2, inserted in pCDNA4 was determined by sequencing from two directions by vector specific primers and compared with the sequence of VP2 gene of IBDV, strain D78 (accession no. AF499929).

COS-7 cells were transfected by pCDNA4VP2 to verify protein expression. The cells cultured in 25cm^3 flasks were transfected with 20 µg plasmid DNA, using lipofect™ Transfection Reagent (Qiagene), as the manufacturer instructions. To verify expression, several clones were tested, due to the differences in expression levels of clones.

The cells were maintained as described above and zeocin was used for selection, 24 h post-transfection. The monolayers were then incubated for another 24 h to obtain maximum expression of VP2.

Twenty four hours after antibiotic selection, liopfected COS-7 cells were harvested by scraping, suspended in PBS and pelleted at 1200 *xg*. After three cycles of freeze-thaw to disrupt the cells, a short centrifugation was performed and the supernatant was used as antigen in dot blotting. Nitrocellulose membranes dotted with the antigen were blocked with 5% skim milk in PBS. VP2 protein was detected using a polyclonal chicken anti-IBDV serum (1:50 dilution), a goat anti-chicken IgG (H+L) peroxidase conjugate (1:30 dilution) and 4-chloro-1 Naphtol (Sigma, USA) peroxidase substrate. Polyclonal and conjugate sera have been produced by KPL company (USA). COS-7 cells, transfected with pCDNA4 were treated in the same manner and used as negative control.

The complete part of segment A encoding the VP2 protein of IBDV strain D78 was successfully amplified with designated primers, from the plasmid pTZ57RVP2. The amplified fragment was ligated to pCDNA4 vector and used for transformation of *Ecoli* strain TOP10F'. The identity of the insert was confirmed by sequencing. Alignment of the insert sequence with the original sequence of VP2 gene of IBDV strain D78 (AF499929) did not show significant differences (Fig. 1).

In order to determine the expression of VP2 in the eukaryotic system, pCDNA4VP2 construct was lipofected in COS-7 cells. The protein expression was detected by dot blotting, on the lysate of the cells, using a polyclonal anti-IBDV chicken serum. The strong reaction of antiserum with the lysate of cells lipofcted with pCDNA4VP2, compared to reaction with lysate of cells lipofected with pCDNA4 (the control), indicated that the protein was successfully expressed (Fig. 2).

IBDV still remains a serious problem for commercial broiler producers. Vaccination is the major tool for the prevention and control of IBD in the poultry industry, but the chickens vaccinated with conventional IBDV vaccines are not fully protected against chal-

```
RT-PCR          ------------------------------------------------------------
RESULT.TXT   1  ACNGATTCGCCAGCTCTATACGACTCACTATAGGGAAAGCTTGCATGCAGGCCTCTGCAG   60

RT-PCR       1  ----------------------GCCGGAATTCATGACAAACCTGCAAGATCAAACCCAAC   38
RESULT.TXT  61  TCGACGGGCCCGGGATCCGATTGCCGGAATTCATGACAAACCTGCAAGATCAAACCCAAC  120

RT-PCR      39  AGATTGTTCCGTTCATACGGAGCCTTCTGATGCCAACAACCGGACCGGCGTCCATTCCGG   98
RESULT.TXT 121  AGATTGTTCCGTTCATACGGAGCCTTCTGATGCCAACAACCGGACCGGCGTCCATTCCGG  180

RT-PCR      99  ACGACACCCTGGAGAAGCACACTCTCAGGTCAGAGACCTCGACCTACAATTTGACTGTGG  159
RESULT.TXT 181  ACGACACCCTGGAGAAGCACACTCTCAGGTCAGAGACCTCGACCTACAATTTGACTGTGG  240

RT-PCR     160  GGGACACAGGGTCAGGGCTAATTGTCTTTTTCCCTGGATTCCCTGGCTCAATTGTGGGTG  220
RESULT.TXT 241  GGGACACAGGGTCAGGGCTAATTGTCTTTTTCCCTGGATTCCCTGGCTCAATTGTGGGTG  300

RT-PCR     221  CTCACTACACACTGCAGAGCAATGGGAACTACAAGTTCGATCAGATGCTCCTGACTGCCC  280
RESULT.TXT 301  CTCACTACACACTGCAGGGCAATGGGAACTACAAGTTCGATCAGATGCTCCTGACTGCCC  360

RT-PCR     281  AGAACCTACCGGCCAGTTACAACTACTGCAGGCTAGTGAGTCGGAGTCTCACAGTGAGGT  340
RESULT.TXT 361  AGAACCTACCGGCCAGTTACAACTACTGCAGGCTAGTGAGTCGGAGTCTCACAGTGAGGT  420

RT-PCR     341  CAGGCACACTTCCTGGTGGCGTTTATGCACTAAACGGCACCATAAACGCCGTGACCTTCC  400
RESULT.TXT 421  CAGGCACACTTCCTGGTGGCGTTTATGCACTAAACGGCACCATAAACGCCGTGACCTTCC  480

RT-PCR     401  AAGGAAGCCTGAGTGAACTGACAGATGTTAGCTACAATGGGTTGATGTCTGCAACAGCCA  460
RESULT.TXT 481  AAGGAAGCCTGAGTGAACTGACAGATGTTAGCTACAATGGGTTGATGTCTGCAACAGCCA  540

RT-PCR     461  ACATCAACGACAAAATTGGGAACGTCCTAGTAGGGGAGGGGGTCACCGTCCTCAGCTTAC  520
RESULT.TXT 541  ACATCAACGACAAAATTGGGAACGTCCTAGTAGGGGAGGGGGTCACCGTCCTCAGCTTAC  600

RT-PCR     521  CCACATCATATGATCTTGGGTATGTGAGGCTTGGTGACCCCATTCCCGCAATAGGGCTTG  580
RESULT.TXT 601  CCACATCATATGATCTTGGGTATGTGAGGCTTGGTGACCCCATTCCCGCAATAGGGCTTG  660

RT-PCR     581  ACCCAAAAATGGTAGCCACATGTGACAGCAGTGACAGGCCCAGAGTCTACACCATAACTG  640
RESULT.TXT 661  ACCCAAAAATGGTAGCCACATGTGACAGCAGTGACAGGCCCAGAGTCTACACCATAACTG  720

RT-PCR     641  CAGCCGATGATTACCAATTCTCATCACAGTACCAACCAGGTGGGGTAACAATCACACTGT  700
RESULT.TXT 721  CAGCCGATGATTACCAATTCTCATCACAGTACCAACCAGGTGGGGTAACAATCACACTGT  780

RT-PCR     701  TCTCAGCCAACATTGATGCCATCACAAGCCTCAGCGTTGGGGGAGAGCTCGTGTTTCAAA  760
RESULT.TXT 781  TCTCAGCCAACATTGATGCCATCACAAGCCTCAGCGTTGGGGGAGAGCTCGTGTTTCAAA  840

RT-PCR     761  CAAGCGTCCACGGCCTTGTACTGGGCGCCACCATCTACCTCATAGGCTTTGATGGGAACG  820
RESULT.TXT 841  CAAGCGTCCACGGCCTTGTACTGGGCGCCACCATCTACCTCATAGGCTTTGATGGGAACA  900

RT-PCR     821  CGGTAATCACCAGGGCTGTGGCCGCAAACAATGGGCTGACGACCGGCACCGACAACCTTT  880
RESULT.TXT 901  CGGTAATCACCAGGGCTGTGGCCGCAAACAATGGGCTGACGACCGGCACCGACAACCTTA  960

RT-PCR     881  TGCCATTCAATCTTGTGATTCCAACAAACGAGATAACCCAGCCAATCACATCCATCAAAC  940
RESULT.TXT 961  TGCCATTCAATCTTGTGATTCCAACAAACGAGATAACCCAGCCAATCACATCCATCAAAC 1020

RT-PCR     941  TGGAGATAGTGACCTCCAAAAGTGGTGGTCAGGCAGGGGATCAGATGTCATGGTCCGCAA 1000
RESULT.TXT 1021 TGGAGATAGTGACCTCCAAAAGTGGTGGTCAGGCAGGGGATCAGATGTCATGGTCGGCAA 1080

RT-PCR    1001  GAGGGAGCCTAGCAGTGACGATCCATGGTGGCAACTATCCAGGGGCCCTCCGTCCCGTCA 1060
RESULT.TXT 1081 GAGGGAGCCTAGCAGTGACGATCCATGGTGGCAACTATCCAGGGGCCCTCCGTCCCGTCA 1140

RT-PCR    1061  CGCTAGTGGCCTACGAAAGAGTGGCAACAGGATCCGTCGTTACGGTCGCTGGGGTGAGCA 1120
RESULT.TXT 1141 CGCTAGTGGCCTACGAAAGAGTGGCAACAGGATCCGTCGTTACGGTCGCTGGGGTGAGCA 1200

RT-PCR    1121  ACTTCGAGCTGATCCCAAATCCTGAACTAGCAAAGAACCTGGTTACAGAATACGGCCGAT 1180
RESULT.TXT 1201 ACTTCGAGCTGATCCCAAATCCTGAACTAGCAAAGAACCTGGTTACAGAATACGGCCGAT 1260

RT-PCR    1181  TTGACCCAGGAGCCATGAACTACACAAAATTGATACTGAGTGAGAGGGACCGTCTTGGCA 1240
RESULT.TXT 1261 TTGACCCAGGAGCCATGAACTACACAAAATTGATACTGAGTGAGAGGGACCGTCTTGGCA 1320

RT-PCR    1241  TCAAGACCGTCTGGCCAACAAGGGAGTACACTGACTTTCGTGAAATACACTTCATGGAGG 1300
RESULT.TXT 1321 TCAAGACCGTCTGGCCAACAAGGGAGTACACTGACTTTCGTGAAATACACTTCATGGAGG 1380

RT-PCR    1301  TGGCCGACCTCAACTCTCCCCTGAAGATTGCAGGAGCATTCGGCTTCAAAGACATAATCC 1360
RESULT.TXT 1381 TGGCCGACCTCAACTCTCCCCTGAAGATTGCAGGAGCATTCGGCTTCAAAGACATAATCC 1440

RT-PCR    1361  GGGCCATAAGGTTTCTAGACGGCAATCTAGATGCTTCGCNGGC  1402
RESULT.TXT 1441 GGGCCATAAGGTTTCTAGACGGC--------------------  1463
```

Figure 1. Alignment of sequence of VP2 gene, obtained in this study, with the sequence of VP2 gene of IBDV D78 strain (accession no. AF499929).



Figure 2. Dot blotting results of transfected cell lysates. Lysate of cells transfected with the constructed expression vector (1 and 2) and the cells transfected with the vector without insert (negative control) (3,4).

lenge with the very virulent strains of IBDV. Therefore, a safer and more efficacious vaccine to control IBD is essential.

Attempts have been made to generate subunit vaccines, by expression of VP2 or virus polyprotein in *Ecoli* (Jagadish *et al*., 1988) and yeast (Pitcovski *et al*., 2003; Goudarzi *et al*., 2006). Recombinant fowlpox viruses containing the genetic material of IBDV have also been developed and tested (Shaw and Davison, 2000).

In recent years several groups have tried the DNA vaccination approach targeting the polyprotein or VP2 of IBDV (Chang *et al*., 2001; Fodor and Fodor, 1999; Hsieh *et al*., 2007; Mahmood *et al*., 2006). DNA vaccination as an alternative approach to vaccinate and protect chickens against IBD has been pursued with some positive and promising results (Hsieh *et al*., 2007, Tang and Johnston, 1992). Application of CpG-ODN as DNA vaccine adjuvant (Mahmood *et al*., 2006), use of bacteria for efficient delivery of DNA vaccine (Mahmood *et al*., 2007; Li *et al*., 2006) and boosting the immune system by a killed vaccine, after using the DNA vaccine (Hsieh *et al*., 2007), all have been shown to enhance the efficacy of IBD DNA vaccines.

Efficacy of IBD DNA vaccine may also depend to other features, like amount of the expressed protein and duration of in vivo expression. In this study, we decided to use pCDNA4 as a vector for expression of IBDV VP2, because it was specifically designed for protein expression in eukaryotic cells but so far, has not been used in IBD DNA vaccine constructions. The plasmid pCDNA4 which is about 5.3 kb contains the CMV promoter, ampicillin resistance gene for selection in *E.coli*, zeocin resistance gene for selection in eukaryotic cell lines and an upstream histidin tag for protein purification.

Based on the results of dot immunoblotting of cells transfected by pCNA4VP2, the construct expresses the protein VP2 of IBDV, but further characterizations are needed to show its usability for *in vivo* expression and immunogenicity of VP2.

Acknowledgements

Special thanks are extended to those individuals and their organizations that have provided help both in time and/or in providing financial support, during the course of the project. They are: Miss Joudaki, Andashti and Daghari for valuable technical assistance, Dr Azadmanesh, Dr Mariami, and Dr. Ebne jalal for the laboratory technical support and Dr Goudarzi for preparation of some materials. National Cell Bank of Iran and plasmid and gene bank of Iran made this project possible with their financial support.

References

Chang HC, Lin TL, Wu CC (2001). DNA mediated vaccination against infectious bursal disease in chickens. *Vaccine* 20: 328-335.

Corr MD, Lee DJ, Carson DA, Tighe H (1996). Gene vaccination with naked plasmid DNA: mechanism of CTL priming. *J Exp Med*. 184: 1555-1560.

Fodor IHE, Fodor N (1999). Induction of protective immunity in chickens immunized with plasmid DNA encoding infectious bursal disease virus antigens. *Acta Vet Hung*. 47: 481-492.

Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL (1993). DNA vaccines: protective immunizations by parenteral mucosal, and genegun inoculations. *Proc Natl Acad Sci USA*. 90: 11478-11482.

Goudarzi H, Seyfiabad Shapouri MR, Toroghi R, Azizy M, Shahbazzadeh D, Pourbakhsh SA (2006). Expression of VP2 protein of classical infectious bursal disease virus in the methylotrophic yeast Pichia pastoris. *Arch of Razi Inst*. 61: 131-136.

Hsieh MK, Wu CC, Lin TL (2007). Priming with DNA vaccine and boosting with killed vaccine conferring protection of chickens against infectious bursal disease. *Vaccine* 25: 7629-7635.

Jagadish MN, Staton VJ, Hudson PJ, Azad AA (1988). Birnavirus precursor polyprotein is processed in Escherichia coli by its own virus-encoded polypeptide. *J Virol*. 62: 1084-1087.

Kibenge FSB, Dhillon AS, Russel RG (1988). Biochemistry and immunology of infectious bursal disease virus. *J Gen Virol*. 69: 1757-1775.

Kibenge FSB, Mckenna PK, Dybing JK (1991). Genomic cloning and analysis of the large RNA segment (seg-

ment A) of a naturally avirulent serotype 2 IBDV. *Virology* 184: 437-440.

Li L, Fang W, Li J, Fang L, Huang Y, Yu L (2006). Oral DNA vaccination with polyprotein gene of infectious bursal disease virus (IBDV) delivered by attenuated Salmonella elicits protective immune responses in chickens. *Vaccine* 24: 5919-5927.

Lukert PD, Saif YM (1997). *Infectious bursal disease virus*. In: Disease of Poultry, 10th Ed, Calnek, *et al*. ed., Iowa State University Press, Ames Iowa, PP. 721-738.

Mahmood MS, Siddique M, Hussain I, Khan A, Mansoor MK (2006). Protection capability of recombinant plasmid DNA vaccine containing VP2 gene of very virulent infectious bursal disease virus in chickens adjuvanted with CpG oligodeoxynucleotide. *Vaccine* 24: 4838-4846.

Mahmood MS, Hussain I, Siddique M, Akhtar M, Ali S (2007). DNA vaccination with VP2 gene of very virulent infectious bursal disease virus (vvIBDV) delivered by transgenic *E. coli* DH5a given orally confers protective immune responses in chickens. *Vaccine* 25: 7629-7635.

Murphy FA, Fauquet CM, Bishop DHL (1995). Virus taxonomy. Classification and nomenclature of virus. Six Report of International Committee on taxonomy of viruses. *Arch viral suppl*. 10: 1481.

Robinson HL, Hunt LA, Webster RG (1993). Protection against a lethal influenza virus challenge by immunization with a hemagglutinin-expressing plasmid DNA. *Vaccine* 11: 957-960.

Sakaguchi M, Nakamura H, Sonoda K, Hamada F, Hirai K (1996). Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus. *Vaccine* 14: 747-752.

Scholz E, Zhang C, Guo P (1993). Transactivation of the early SV40 promoter by avian infectious laryngotracheitis virus in avian hepatoma cells. *J Virol Methods*. 45: 291-301.

Shaw I, Davison TF (2000). Protection from IBDV-induced bursal damage by a recombinant fowlpox vaccine, fpIBDV, is dependent on the titre of challenge virus and chicken genotype. *Vaccine* 18: 3230-3241.

Tang DC, Johnston SA (1992). Genetic immunization is a simple method for eliciting an immune response. *Nature* 356: 152-154.

Tsukamoto K, Tanimura N, Kakita S, Ota K, Mase M, Imai K, Hibara H (1995). Efficacy of three live vaccines against highly virulent infectious bursal disease virus and the optimum vaccination. *Avian Dis*. 39: 218-229.

Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, Dewitt CM, Friedman A *et al*. (1993). Heterologous protection against influenza by injection of DNA encoding a viral protein. *Science* 259: 1745-l 749.

Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990). Direct gene transfer into mouse muscle *in vivo*. *Science* 247: 1465-1468.